| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085936151 |
| P356 | DOI | 10.1007/S10637-017-0480-X |
| P698 | PubMed publication ID | 28597151 |
| P50 | author | Jean-Charles Soria | Q33120580 |
| Sophie Postel-Vinay | Q41745309 | ||
| P2093 | author name string | Xavier Paoletti | |
| Andrea Varga | |||
| Christophe Massard | |||
| Jean-Marie Michot | |||
| Vincent Ribrag | |||
| David Ghez | |||
| Sophie Postel-Vinay | |||
| Lina Benajiba | |||
| Alina Danu | |||
| Antoine Hollebecque | |||
| Anas Gazzah | |||
| Camille Bigenwald | |||
| Frederic Bigot | |||
| Benjamin Verret | |||
| Capucine Baldini | |||
| Rastilav Balheda | |||
| Julien Lazarovici | |||
| Laura Faivre | |||
| Aurore Jeanson | |||
| Clement Bonnet | |||
| Lelia Haddag | |||
| Zoé A P Thomas | |||
| P2860 | cites work | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| Reporting methods in studies developing prognostic models in cancer: a review | Q30494142 | ||
| Phase 0 clinical trials in oncology new drug development | Q34941964 | ||
| The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications | Q35029409 | ||
| Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience | Q36510136 | ||
| Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. | Q37016543 | ||
| Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes | Q37304122 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system | Q38948345 | ||
| Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? | Q42697940 | ||
| Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience | Q43522124 | ||
| Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials | Q45274026 | ||
| Prospective validation of a prognostic score to improve patient selection for oncology phase I trials | Q46068560 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Redefining dose-limiting toxicity | Q48334170 | ||
| Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors | Q53658356 | ||
| Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G | Q56784798 | ||
| Follicular lymphoma: prognostic factors for response and survival | Q68902176 | ||
| Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials | Q73668726 | ||
| Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) | Q81341430 | ||
| Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? | Q83737803 | ||
| P921 | main subject | phase I clinical trial | Q5452194 |
| P577 | publication date | 2017-06-09 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials |
Search more.